amg-191
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02963064)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109325 ↗
Also known as
- amg191
- amg-191
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02963064 | Phase 1 | Aug 1, 2016 | California Institute for Regenerative Medicine, Stanford University, University of California, San Francisco |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1